Sarepta Gene Therapy Paused After Patient Death
- Sarepta therapeutics is facing scrutiny after a second patient died following treatment with Elevidys, its gene therapy for Duchenne muscular dystrophy.
- The Cambridge, MA, firm is now developing enhanced safety protocols to address the risk of liver injury associated with Elevidys.
- Duchenne muscular dystrophy, a rare genetic condition primarily affecting boys, results from insufficient dystrophin, a vital muscle protein.
Sarepta‘s gene therapy,Elevidys,faces a critical safety review after a second patient death linked to liver failure. sarepta has paused shipments to non-ambulatory Duchenne muscular dystrophy patients, prompting immediate action. The company is now enhancing safety protocols to address the inherent risks of this innovative treatment, including consultation with a panel of experts to refine immunosuppression strategies and consider sirolimus. This growth,reported by News Directory 3,underscores the complexities of gene therapy and the continuous need to balance potential benefits with patient safety. Sarepta’s leading product, which generated important revenue in 2024, is under the microscope. Discover what’s next as the FDA reviews recommendations.
Sarepta Gene Therapy Death Prompts Safety Review for Duchenne Treatment
Updated June 16, 2025
Sarepta therapeutics is facing scrutiny after a second patient died following treatment with Elevidys, its gene therapy for Duchenne muscular dystrophy. The company reported the death Sunday, noting the patient, like the first fatality, experienced acute liver failure.
The Cambridge, MA, firm is now developing enhanced safety protocols to address the risk of liver injury associated with Elevidys. As a precaution, Sarepta is suspending shipments of the gene therapy to patients who are no longer able to walk due to the progression of their Duchenne muscular dystrophy.
Duchenne muscular dystrophy, a rare genetic condition primarily affecting boys, results from insufficient dystrophin, a vital muscle protein. The disease leads to muscle degeneration, loss of mobility, and, often, death in the patient’s 20s or 30s due to heart and lung complications.
Elevidys uses a modified virus to deliver a gene that enables muscle cells to produce microdystrophin, a shortened version of the protein. Though, this delivery method carries a risk of triggering excessive immune responses, which can be managed with immunosuppressants. The dosage is weight-based, meaning older, heavier patients receive higher doses and, consequently, greater exposure to the virus, increasing the risk of adverse reactions.
Sarepta plans to consult with an self-reliant panel of experts in Duchenne and liver health to refine the Elevidys immunosuppression strategy. The company is suggesting adding sirolimus, an immunosuppressant approved in 1999, based on data indicating it can moderate elevated liver enzyme levels. the FDA will review the panel’s recommendations, and any changes to the Elevidys treatment plan depend on regulatory approval.
Elevidys has quickly become Sarepta’s leading product, generating $820.8 million in revenue in 2024, a critically important increase from $200.3 million the previous